TA
Tolka AI Therapeutics develops personalized phage therapy using bacteriophages to target and eliminate antibiotic-resistant bacterial infections. This approach minimizes side effects by exclusively attacking pathogenic bacteria, addressing the urgent global health crisis of antibiotic resistance.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Tolka AI Therapeutics develops personalized phage therapy using bacteriophages to target and eliminate antibiotic-resistant bacterial infections. This approach minimizes side effects by exclusively attacking pathogenic bacteria, addressing the urgent global health crisis of antibiotic resistance.